RX-TO-OTC SWITCHES GIVE WHOLESALERS "CLEAR OPPORTUNITY" TO HELP RETAILERS

RX-TO-OTC SWITCHES GIVE WHOLESALERS "CLEAR OPPORTUNITY" TO HELP RETAILERS make pricing and merchandising decisions, Dan Raftery, VP at Willard Bishop Consulting, said March 10 at the National Wholesale Druggists Association's marketing conference in Dallas. Raftery explained that Rx-to-OTC switches "are very complex products" requiring "some education by the wholesaler." This education should take the form of not only an "initial commitment," he said, but should also be seen as an "ongoing opportunity" to help retailers. Raftery said that OTC vendors without pharmacies are especially in need of education and support for Rx-to-OTC switch products. "They won't be experienced with prescription products, they won't know what to compare these items to," he explained. Such retailers also will have problems understanding the higher prices of switch products, Raftery indicated. He emphasized, however, that "you cannot use price alone in this area. As a distributor you have the opportunity to provide some value-added [service]." Retailers will need "to understand the complexities and applications" of products that were once behind the counter, Raftery said. Raftery was one of several speakers at the NWDA conference who encouraged wholesalers to help independent drug stores and food markets compete with drug chains, food stores, and mass merchandisers in OTC sales by providing managerial and technical assistance. For example, NWDA Chairman Dwight Steffensen (president and chief operating officer, Bergen Brunswig) said March 10 that drug wholesalers "must collectively design innovative approaches that will ensure that consumer products are available in broad-base distribution in all channels of trade, especially independent pharmacy." He said that "this can only happen when we commit to being players in the consumer products arena." As an example of what wholesalers can do for independent retailers, Steffensen suggested "helping customers implement point-of-sale technology." Industry consultant David Hamacher, D.P. Hamacher & Associates observed that "wholesalers can help encourage technology advancement" by retailers, particularly point-of-sale data gathering, which he said "will be key for independent retailers" in competing with larger rivals. Other areas where Hamacher said wholesalers can assist independent OTC retailers include assisting in inventory management "to cut down on out-of-stock items"; "identifying niches" where a retailer might build an advantage; and providing staff training. Superior customer service "is where [independents] can have an advantage," he maintained. Hamacher and industry consultant Anthony DiNicola, A and D Associates, also pointed to advertising, plan-o-gram development and maintenance; end-cap programs; and seasonal/promotional aisles.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

BIO Notebook: MFN Pricing, Obesity R&D, US FDA’s Rare Disease Hub And Reaction To Review Program

Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.